CD38 and Miyoshi myopathy: Daratumumab, a therapeutic anti-CD38 monoclonal antibody approved for treatment of MM, facilitates Complement-Dependent Cytotoxicity, Antibody-Dependent Cellular Phagocytosis, and ADCC against CD38+ MM cells [73, 74].